MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immuneering Corporation - Class A Common Stock (NQ:IMRX)

3.710 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immuneering Corporation - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
3 Stocks Insiders Are Buying That Analysts Love
Insiders are buying these stocks that analysts view as undervalued. Each has a potential catalyst in the works, and its shares could advance triple digits. 
Via MarketBeat
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI
Via AB Newswire
News headline image
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Cancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Data ↗
Immuneering shares dip as analysts express concern over IMM-1-104 trial results. Needham downgrades, citing efficacy issues despite promising mechanism of action. Optimism remains for earlier-stage... 
Via Benzinga
News headline image
Dow Falls Over 200 Points; Adobe Shares Plunge ↗
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points on Friday. The Dow traded down 0.55% to 38,692.43 while the NASDAQ fell 0.90% to 15,982.65. The S&P... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter results and issued FY25 guidance below estimates. 
Via Benzinga
News headline image
Crude Oil Edges Lower; US Consumer Sentiment Falls In March ↗
U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points on Friday. The Dow traded down 0.37% to 38,761.74 while the NASDAQ fell 0.95% to 15,974.83. The S&P 500... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates. 
Via Benzinga
News headline image
What's Going On With Cancer-Focused Immuneering Stock On Thursday? ↗
Unlock the latest Phase 1 trial results for IMM-1-104 by Immuneering. Discover how 320mg and 240mg doses inhibit tumor progression and evaluate safety profiles. 
Via Benzinga
News headline image
US Stocks Higher; Producer Prices Rise 0.6% In February ↗
U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.11% to 39,084.58 while the NASDAQ rose 0.30% to 16,226.13. The S&P... 
Via Benzinga
Topics Stocks
News headline image
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directors
Former Chairman, CEO and Founder of ChemoCentryx, Inc. 
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
From Immuneering Corporation
Via GlobeNewswire
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth
EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
News headline image
3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave ↗
Explore hidden-gem biotech stocks set for growth in a booming market. Uncover top picks ready to redefine healthcare innovation. 
Via InvestorPlace
News headline image
Immuneering Announces Participation in February Investor Conferences
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
From Immuneering Corporation
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Immuneering Corporation
Via GlobeNewswire
News headline image
Immuneering to Present at the Morgan Stanley Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story